MedPath
HSA Approval

ERYCYN-250 TABLET 250 mg

SIN11952P

ERYCYN-250 TABLET 250 mg

ERYCYN-250 TABLET 250 mg

May 25, 2002

NAINA MOHAMED & SONS PRIVATE LIMITED

NAINA MOHAMED & SONS PRIVATE LIMITED

Regulatory Information

NAINA MOHAMED & SONS PRIVATE LIMITED

NAINA MOHAMED & SONS PRIVATE LIMITED

Therapeutic

Prescription Only

Formulation Information

TABLET, FILM COATED

**DOSAGE AND ADMINISTRATION:** 250 mg 6 hrly; the dose may be doubled for severe infections. Gonorrhoea: 500 mg 6 hrly for 6–7 days Syphilis: 1gm 6hrly for 10–15 days (30days in late syphilis) Prophylaxis against streptococci: 250mg 12 hrly.

ORAL

Medical Information

**INDICATIONS & USES:** Upper and lower respiratory tract infections; Mycoplasma and Chlamydial infections; Skin and soft tissue infections; Diphtheria; Legionnaires disease; Otitis media; Pertussis; Chancroids.

**CONTRAINDICATIONS:** - Erythromycin is contraindicated in patients taking astemizole, terfenadine, domperidone, cisapride or pimozide - Erythromycin should not be given to patients with a history of QT prolongation (congenital or documented acquired QT prolongation) or ventricular cardiac arrhythmia, including torsades de pointes (see “Warnings and Precautions” – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_) - Erythromycin should not be given to patients with electrolyte disturbances (hypokalaemia, hypomagnesaemia due to the risk of prolongation of QT interval)

J01FA01

erythromycin

Manufacturer Information

NAINA MOHAMED & SONS PRIVATE LIMITED

MICRO LABS LTD

Active Ingredients

ERYTHROMYCIN STEARATE EQV ERYTHROMYCIN

250 mg

Erythromycin

Documents

Package Inserts

Erycyn 250 PI Clear version-10.11.2020.pdf

Approved: January 20, 2021

Download
© Copyright 2025. All Rights Reserved by MedPath